TEM Stock Drops Before Q1 Earnings, Notetaker AI Launch

The shares of Tempus AI Inc (TEM) have experienced a 1.7% decline to $53.15 on Tuesday afternoon. The company is set to report its first-quarter earnings after the market closes on Tuesday, with analysts anticipating a loss of 27 cents per share on revenue of $248.13 million.

The release of Notetaker, an AI clinical assistant that simplifies psychiatric documentation by recording sessions and producing notes for electronic health records, took place on Monday prior to this earnings report. Notetaker, accessible via Tempus Hub, bolsters the company’s mental health platform with various features, including multilingual transcription, pharmacogenomic insights, and secure data storage compliant with HIPAA regulations.

Recently, Tempus has expanded its partnership with AstraZeneca and Pathos AI to develop a multimodal foundation model for oncology under a $200 million agreement. This collaboration aims to enhance cancer therapeutics utilizing Tempus’ de-identified data.

During the fourth quarter, Tempus reported revenue of $200.68 million, which represented a 35.8% increase year-over-year, while also reporting a narrower-than-anticipated loss of $0.18 per share. The company finished the quarter with $940 million in remaining contract value and projects robust growth for 2025, targeting revenue of $1.24 billion and positive adjusted EBITDA.

Furthermore, retail investor interest in Tempus has surged, partly attributed to substantial options purchases made by former House Speaker Nancy Pelosi earlier this year.

In terms of stock purchase options, investors seeking to acquire shares of TEM can do so through brokerage platforms either by purchasing shares or fractional shares of the stock directly. Alternatively, investors can gain exposure to TEM through ETFs tracking the Health Care sector, which typically hold shares in various liquid and large companies within this segment.

According to data from Benzinga Pro, TEM has recorded a 52-week high of $91.45 and a 52-week low of $22.89.